News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Amgen Gets Priority Review For Prolia
July 19, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- Amgen has received a boost with the news that regulators in the USA have granted a priority review to the company’s recently-approved denosumab, this time for the reduction of skeletal related events in advanced cancer patients.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Regulatory
MORE ON THIS TOPIC
Manufacturing
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
September 24, 2026
·
2 min read
·
Nick Paul Taylor
Approvals
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
September 24, 2026
·
1 min read
·
Annalee Armstrong
Kidney disease
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
September 23, 2026
·
2 min read
·
Annalee Armstrong
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
·
2 min read
·
Jef Akst
